New treatment paradigm of older patient with AML
In this MEDtalk, Marina Konopleva, MD, PhD, and professor in section of leukemia biology research, guides you through the newest findings on older patients with AML. The studies presented focus on treatment options for older patients with AML, mostly IDH1-2-, FLT3-, and TP53 mutated AML, ineligible for intensive chemotherapy. More treatment regimens are showing promising results in overall survival, indicating a new treatment approach.
